Publications by authors named "C Bucelli"
Chronic Myeloid Leukemia (CML) is marked by the BCR::ABL1 fusion gene. Monitoring tyrosine kinase inhibitor (TKI) therapy response is crucial for treatment management, thus, limitations in Reverse Transcription quantitative PCR's (RT-qPCR) accuracy and sensitivity led to the exploration of alternative methods like digital PCR (dPCR). This study evaluated dPCR efficacy in detecting Minimal Residual Disease (MRD) in CML patients undergoing TKI therapy.
View Article and Find Full Text PDFArticle Synopsis
- Up to 30% of chronic myeloid leukemia (CML) patients may need a treatment change due to issues with first-line tyrosine kinase inhibitors (TKIs), and bosutinib (BOS) emerges as an effective and safe alternative.
- A study analyzed 132 CML patients treated with BOS across 18 hematology centers, finding that most patients switched due to intolerance to previous TKIs, with a significant number achieving positive treatment outcomes.
- The findings suggest that BOS is a preferred treatment choice, particularly for patients who cannot tolerate previous TKIs, demonstrating its safety and effectiveness in real-life settings.
Article Synopsis
- - The introduction of small molecule tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) has significantly improved patient life expectancy, making it comparable to the general population, despite potential mild to severe side effects from long-term use.
- - Emerging goals in CML treatment include the potential for treatment-free remission (TFR), with specific eligibility criteria, where 25%-30% of patients might achieve prolonged TFR.
- - This review focuses on guidelines for safely stopping TKIs, shares clinical insights from trials and real-world data, and highlights ongoing research into biological markers that could help predict TFR success.
Article Synopsis
- The study evaluated the use of frontline TKI therapy in elderly patients (75 years or older) with chronic phase chronic myeloid leukemia (CP-CML) among a large cohort of 332 patients.
- Results showed that 85.8% of patients received imatinib (IM), while 14.2% were treated with second-generation TKIs (2G-TKI) like dasatinib and nilotinib, with a notable percentage starting on reduced doses.
- The findings indicated increased usage of IM after generic versions became available in Italy, but significant discontinuation rates due to resistance and toxicities were observed, highlighting the need for personalized treatment assessments and further studies on lower TKI doses.
Purpose Of Review: Myelofibrosis (MF) includes prefibrotic primary MF (pre-PMF), overt-PMF and secondary MF (SMF). Median overall survival (OS) of pre-PMF, overt-PMF and SMF patients is around 14 years, seven and nine years, respectively. Main causes of mortality are non-clonal progression and transformation into blast phase.
View Article and Find Full Text PDF